James Legg
Chief Scientific Officer Cytospire Therapeutics Ltd
Dr. James Legg Ph.D is the Chief Scientific Officer at Cytospire Therapeutics. James was previously SVP Research and Early Development at Mestag Therapeutics, joining soon after its inception and helping to build its portfolio of biologics targeting specialised fibroblast populations in oncology and stromal checkpoint agonism in inflammatory and autoimmune disease. Prior to Mestag, James was SVP Research and Development at Crescendo Biologics.
James started his career at Cambridge Antibody Technology/AstraZeneca/MedImmune and has also consulted for a number of early stage biotechnology companies.
James holds a first class degree in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research at Imperial Cancer Research Fund (Now CRUK) in London.
Seminars
- Gamma delta T-cells combine innate potency with adaptive durability, enabling rapid and sustained immune responses that are naturally suited to discriminating diseased from healthy cells
- Gamma delta T-cell engagers leverage this unique biology to activate tumour-relevant effector cells while avoiding broad immune activation, supporting effective tumour killing with a lower risk of cytokine-driven toxicity
- Cytospire’s multispecific TCE platform activates all gamma delta T-cell subsets, including tissue-resident populations, overcoming patient heterogeneity to unlock more consistent, scalable efficacy in solid tumours
